objective(s): first principles calculations were performed to study four multiple sclerosis drugs namely, ampyra, fingolimod, mitoxantrone and eliprodil in gas and liquid phases using density functional theory (dft). computational chemistry simulations were carried out to compare calculated quantum chemical parameters for ampyra, fingolimod, mitoxantrone and eliprodil. materials and methods: al...

background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...

conclusions our study suggests that the personality traits of patients with ms and healthy individuals are not significantly different. patients with ms are likely to use the same coping strategies as healthy individuals, except in the subscale of distancing. results no significant differences in personality characteristics were observed between patients and healthy controls (all p > 0.05). onl...

background: multiple sclerosis is accompanied by secondary clinical signs such as insomnia. considering the side effects of drugs and also increasing acceptability of psychotherapy methods in health systems, we aimed to determine the effect of group cognitive behavioral therapy on the quality of sleep in women with multiple sclerosis in 2014. methods: this study is a randomized controlled clini...

Multiple sclerosis is a disease that characterized by the nervous system injury. The pathophysiology unknown, but it supposed caused an increase of immune response to myelin sheath, which causes damage in system. Actually, there are lot immunomodulatory drugs control this pathology. One most important aspects fact irreversible; therefore, use for illness just symptoms; nevertheless, some review...

background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reductio...

OBJECTIVES To examine associations between medication use and health-related quality of life (HRQOL), relapse rate and disability in an international cohort of people with multiple sclerosis (PwMS). METHODS Using Web 2.0 platforms, the authors recruited PwMS who completed survey items on demographics, medication use, HRQOL, relapse rate and disability. RESULTS Of 2276 respondents from 56 co...

There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA...